Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-07-10
DOI
10.1038/s41598-018-28449-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes
- (2017) María Molina Vega et al. Expert Opinion on Drug Metabolism & Toxicology
- Exenatide: pharmacokinetics, clinical use, and future directions
- (2017) Filip K. Knop et al. EXPERT OPINION ON PHARMACOTHERAPY
- Epidemiology of Parkinson’s disease
- (2017) Ole-Bjørn Tysnes et al. JOURNAL OF NEURAL TRANSMISSION
- Effects of diet and insulin on dopamine transporter activity and expression in rat caudate-putamen, nucleus accumbens, and midbrain
- (2017) Kymry T. Jones et al. JOURNAL OF NEUROCHEMISTRY
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
- (2017) Dilan Athauda et al. LANCET
- Projection of the prevalence of Parkinson's disease in the coming decades: Revisited
- (2017) Alexander Rossi et al. MOVEMENT DISORDERS
- Parkinson disease: Exenatide – a drug for diabetes and Parkinson disease?
- (2017) Joseph Jankovic Nature Reviews Neurology
- A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease
- (2017) Jaishree Jalewa et al. NEUROPHARMACOLOGY
- Is Exenatide a Treatment for Parkinson’s Disease?
- (2017) Dilan Athauda et al. Journal of Parkinsons Disease
- Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
- (2017) Hamish Courtney et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease
- (2016) Henrik H Hansen et al. BRAIN RESEARCH
- Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program
- (2016) Hui Peng et al. Current Diabetes Reports
- Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials
- (2016) Karolin Bettge et al. DIABETES OBESITY & METABOLISM
- The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action
- (2016) Dilan Athauda et al. DRUG DISCOVERY TODAY
- PI3K/AKT signaling mediated by G protein-coupled receptors is involved in neurodegenerative Parkinson's disease (Review)
- (2016) Noriko Nakano et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Degeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson’s Disease
- (2016) Juhyun Song et al. Frontiers in Aging Neuroscience
- Is Axonal Degeneration a Key Early Event in Parkinson’s Disease?
- (2016) Zuzanna Kurowska et al. Journal of Parkinsons Disease
- Parkinson-like phenotype in insulin-resistant PED/PEA-15 transgenic mice
- (2016) Giuseppe Perruolo et al. Scientific Reports
- Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease
- (2015) W. Liu et al. NEUROSCIENCE
- Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
- (2015) Matthieu F. Bastide et al. PROGRESS IN NEUROBIOLOGY
- Insulin enhances striatal dopamine release by activating cholinergic interneurons and thereby signals reward
- (2015) Melissa A. Stouffer et al. Nature Communications
- Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
- (2015) Iciar Aviles-Olmos et al. Journal of Parkinsons Disease
- Exenatide as a potential treatment for patients with Parkinson's disease: First steps into the clinic
- (2014) Thomas Foltynie et al. Alzheimers & Dementia
- Pharmacokinetic Properties and Effects of PT302 After Repeated Oral Glucose Loading Tests in a Dose-Escalating Study
- (2014) Namyi Gu et al. CLINICAL THERAPEUTICS
- Role of ERK signaling in activity-dependent modifications of histone proteins
- (2014) Alessandro Ciccarelli et al. NEUROPHARMACOLOGY
- Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
- (2014) Fares Bassil et al. PROGRESS IN NEUROBIOLOGY
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
- (2013) Jonathan E. Campbell et al. Cell Metabolism
- Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease
- (2013) Simon R.W. Stott et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- Exenatide and the treatment of patients with Parkinson’s disease
- (2013) Iciar Aviles-Olmos et al. JOURNAL OF CLINICAL INVESTIGATION
- The current and projected economic burden of Parkinson's disease in the United States
- (2013) Stacey L. Kowal et al. MOVEMENT DISORDERS
- Parkinson's disease, insulin resistance and novel agents of neuroprotection
- (2012) Iciar Aviles-Olmos et al. BRAIN
- Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders
- (2012) Isidro Salcedo et al. BRITISH JOURNAL OF PHARMACOLOGY
- Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat
- (2012) Amjad Abuirmeileh et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Akt as a Victim, Villain and Potential Hero in Parkinson’s Disease Pathophysiology and Treatment
- (2011) Lloyd A. Greene et al. CELLULAR AND MOLECULAR NEUROBIOLOGY
- Diabetes and Risk of Parkinson's Disease
- (2011) Q. Xu et al. DIABETES CARE
- Insulin resistance impairs nigrostriatal dopamine function
- (2011) J.K. Morris et al. EXPERIMENTAL NEUROLOGY
- Animal models of Parkinson's disease
- (2011) Vernice Jackson-Lewis et al. PARKINSONISM & RELATED DISORDERS
- Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet
- (2010) Jill K. Morris et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Effects of intrastriatal GDNF on the response of dopamine neurons to 6-hydroxydopamine: Time course of protection and neurorestoration
- (2010) Ann D. Cohen et al. BRAIN RESEARCH
- Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease
- (2009) Sehee Kim et al. JOURNAL OF ENDOCRINOLOGY
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
- (2009) Y. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prospective Cohort Study of Type 2 Diabetes and the Risk of Parkinson's Disease
- (2008) J. A. Driver et al. DIABETES CARE
- Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease
- (2008) Alexander Harkavyi et al. Journal of Neuroinflammation
- Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease
- (2007) Göran Bertilsson et al. JOURNAL OF NEUROSCIENCE RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More